PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down

Phibro Animal Health (PAHC) reported robust fiscal Q4 2025 results, with adjusted EPS of $0.57 and net sales of $378.7 million, both significantly exceeding analyst estimates, primarily driven by a 53% increase in Animal Health sales. Despite a 287 basis point contraction in gross margin, the company's shares surged 18% in after-hours trading, buoyed by strong fiscal 2026 guidance projecting 12% sales growth and a 25% increase in adjusted EPS, signaling continued confidence in its core segment's momentum.

Analysis

Phibro Animal Health (PAHC) reported a robust fourth quarter for fiscal 2025, significantly exceeding consensus estimates on both revenue and earnings, which triggered an 18% after-hours stock surge. Net sales grew 38.6% year-over-year to $378.7 million, while adjusted EPS increased to $0.57 from $0.41 in the prior-year quarter. The primary driver of this outperformance was the Animal Health segment, which saw sales surge 53%, largely fueled by $94.5 million in incremental revenues from the recently acquired Zoetis MFA portfolio. Despite the strong top-line growth, a key point of concern is the 287 basis point contraction in gross margin to 29.1%, stemming from a 44.5% rise in the cost of goods sold. However, this pressure was more than offset at the operating level, where disciplined SG&A expense management (up only 11.1%) led to an 82.2% increase in operating profit and a 213 basis point expansion in operating margin to 8.9%. The company's bullish fiscal 2026 guidance, projecting 12% sales growth and a 25% increase in adjusted EPS to a range of $2.52-$2.70, substantially outpaces current analyst expectations and signals strong management confidence.

Key Decisions for Investors

• Given the strong earnings beat and forward guidance that significantly exceeds consensus, investors may view the positive market reaction as justified, but should assess if the growth from the Zoetis acquisition is fully priced in after the 18% share price increase.
• The 287 basis point contraction in gross margin is a critical risk factor; investors should closely monitor future cost of goods sold trends and the company's ability to maintain pricing power to protect profitability.
• It is prudent to track the performance of the core Animal Health segment and the integration of the Zoetis portfolio, as this remains the central pillar of the company's growth narrative and the primary driver of its optimistic 2026 outlook.
• Note the decline in cash on hand and operating cash flow, which could warrant scrutiny in subsequent quarters to ensure the company's strong earnings growth translates into robust free cash flow generation.